What If First Treatments Fail?

Transcript

Unfortunately with stage four, eventually people progress through all of these kind of initial backbone management strategies. There are options that exist after failure on these therapies, especially if that MMR status or MSI high status relating to immune therapy also is not an option, or you’ve progressed on immune therapy.

Some of these agents are called regorafenib, trifluridine, tipiracil, otherwise known as TAS102, as well as some drugs in clinical trials that attack other actionable mutations that we don’t have as standard of care yet. These are drugs that you really want to carefully consider with your doctor because of the side effect profile and what may be going on with you individually.

Key Takeaways

1. Unfortunately with stage four, eventually people progress through the initial backbone treatments.

2. There are options that exist after failure on these therapies, especially if immune therapy is not an option.

3. Some of these agents are called regorafenib, trifluridine, tipiracil, otherwise known as TAS102.

4. These are drugs that you want to carefully consider with your doctor because of potential side effects.